Qualify For a Study or Trial

The ILLUMINATE Studies are phase 2 clinical research studies evaluating the safety and effectiveness of an investigational medication designed to reduce or eliminate the negative immune response to gluten in adults with celiac disease. In order to qualify, one must:

• Be between 18 and 75 years old
• Have biopsy-confirmed celiac disease
• Have been on a gluten-free diet for at least the past 6 months

Some study visits can be completed at home, and all study-related care will be provided at no cost. Participants may be compensated for time + travel.

To learn more, please visit: illuminatecd.com/cdf.

This phase 1 clinical study is evaluating the safety of the study medication, DONQ52.

This medication is designed to target an immune complex known to cause celiac disease symptoms. This may protect the small intestine of a person with celiac disease.

There is no gluten challenge in this study. You may be compensated for time and travel.

Requirements:

• You are 18-70 years old
• You have celiac disease
• You are already on a gluten-free diet for at least 12 months
• Have or can obtain medical records which show diagnosis of celiac disease
• Other requirements will apply.

If you’re interested in the study, think you may qualify, or want to find a study site location near you, visit www.celiacdiseasestudy.com.

The CeDar Rose Study is a remote celiac disease study that will monitor individual gluten intolerance. This is an observational study; no study drug is associated with this study. You may be assigned to a gluten challenge.

You may be compensated for your participation.

Study requirements:

• You are 18-70 years old
• Have medically diagnosed celiac disease
• You are already on a gluten-free diet for at least 12 months
• Other requirements will apply.

If you’re interested in this study and want to learn more, please visit: celiacobservationalstudy.com

The goal of this phase 2 clinical trial is to test the safety and effects of the investigational medication PRV-015.

In combination with a gluten-free diet, PRV-015 aims to reduce symptoms and intestinal inflammation caused by accidental gluten exposure.

NO gluten challenge

Requirements:

• 18-70 years old
• Biopsy-confirmed celiac disease
• On a gluten-free diet for at least the last 12 months
• Still experiencing celiac disease symptoms

Learn more at proactiveceliac.com
Use referral code: REFCDF

The KAN-101-02 Study is a phase 1b/2 clinical trial testing the safety and tolerability of the investigational medication KAN-101.

KAN-101 targets the immune cells that drive celiac disease and leaves the otherwise healthy components of the immune system intact. KAN-101 acts by re-educating T cells, or tolerizing them, so they do not respond to gluten antigens.

Requirements:

• 18-70 years
• Biopsy-confirmed celiac disease
• On gluten-free diet for at least the last 12 months

Learn more at clinicaltrials.gov/ct2/show/NCT05574010